Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.
2.

Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning.

Yuan QA, Robinson MK, Simmons HH, Russeva M, Adams GP.

Cancer Immunol Immunother. 2008 Mar;57(3):367-78. Epub 2007 Aug 4.

PMID:
17676323
3.

Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.

Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I, Cliby WA.

Gynecol Oncol. 2008 Jan;108(1):141-8. Epub 2007 Nov 7.

PMID:
17988723
4.

Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.

Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK.

Clin Cancer Res. 1999 Nov;5(11):3488-99.

5.

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.

McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM.

Mol Immunol. 1999 May;36(7):433-45.

PMID:
10449096
6.

Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.

Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF, MacLaughlin DT.

Clin Cancer Res. 2006 Mar 1;12(5):1593-8.

7.

Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor.

Figini M, Martin F, Ferri R, Luison E, Ripamonti E, Zacchetti A, Mortarino M, Di Cioccio V, Maurizi G, Allegretti M, Canevari S.

Cancer Immunol Immunother. 2009 Apr;58(4):531-46. doi: 10.1007/s00262-008-0575-5. Epub 2008 Aug 15.

PMID:
18704410
8.

Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines.

Rothe A, Klimka A, Tur MK, Pfitzner T, Huhn M, Sasse S, Mallmann P, Engert A, Barth S.

Int J Mol Med. 2004 Oct;14(4):729-35.

PMID:
15375609
9.

Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.

Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC.

Cancer Res. 2003 Mar 15;63(6):1389-97.

10.

Characterization of a putative ovarian oncogene, elongation factor 1alpha, isolated by panning a synthetic phage display single-chain variable fragment library with cultured human ovarian cancer cells.

Sharma S, Tammela J, Wang X, Arnouk H, Driscoll D, Mhawech-Fauceglia P, Lele S, Kazim AL, Odunsi K.

Clin Cancer Res. 2007 Oct 1;13(19):5889-96.

11.
12.

Selection of tumor-specific internalizing human antibodies from phage libraries.

Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD.

J Mol Biol. 2000 Sep 1;301(5):1149-61.

PMID:
10966812
13.

Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse.

Brocks B, Garin-Chesa P, Behrle E, Park JE, Rettig WJ, Pfizenmaier K, Moosmayer D.

Mol Med. 2001 Jul;7(7):461-9.

14.

Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2).

Cheng LS, Liu AP, Yang JH, Dong YQ, Li LW, Wang J, Wang CC, Liu J.

Cell Res. 2003 Feb;13(1):35-48.

15.

The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.

Song JY, Chen KY, Kim SY, Kim MR, Ryu KS, Cha JH, Kang CS, MacLaughlin DT, Kim JH.

Int J Oncol. 2009 Jun;34(6):1583-91.

PMID:
19424576
16.

Isolating and engineering human antibodies using yeast surface display.

Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD.

Nat Protoc. 2006;1(2):755-68.

PMID:
17406305
17.

Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins.

Myers KA, Ryan MG, Stern PL, Shaw DM, Embleton MJ, Kingsman SM, Carroll MW.

Cancer Gene Ther. 2002 Nov;9(11):884-96.

18.

Generation of affinity matured scFv antibodies against mouse neural cell adhesion molecule L1 by phage display.

Dong L, Chen S, Bartsch U, Schachner M.

Biochem Biophys Res Commun. 2003 Jan 31;301(1):60-70.

PMID:
12535641
19.

Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.

Kioi M, Seetharam S, Puri RK.

Mol Cancer Ther. 2008 Jun;7(6):1579-87. doi: 10.1158/1535-7163.MCT-07-2131.

20.

Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer.

Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC.

Cancer Biol Ther. 2007 Nov;6(11):1717-25. Epub 2007 Aug 3.

PMID:
17986851

Supplemental Content

Support Center